RU2014151103A - APPLICATION OF COMPOUNDS OF THE CLASS OF 1,3,4-THIADIAZIN AND THEIR PHARMACEUTICAL COMPOSITION WITH ASCORBIC ACID AS A MEANS OF CORRECTION OF EXPERIMENTAL ALLOXAN SUGAR DIABETES - Google Patents

APPLICATION OF COMPOUNDS OF THE CLASS OF 1,3,4-THIADIAZIN AND THEIR PHARMACEUTICAL COMPOSITION WITH ASCORBIC ACID AS A MEANS OF CORRECTION OF EXPERIMENTAL ALLOXAN SUGAR DIABETES Download PDF

Info

Publication number
RU2014151103A
RU2014151103A RU2014151103A RU2014151103A RU2014151103A RU 2014151103 A RU2014151103 A RU 2014151103A RU 2014151103 A RU2014151103 A RU 2014151103A RU 2014151103 A RU2014151103 A RU 2014151103A RU 2014151103 A RU2014151103 A RU 2014151103A
Authority
RU
Russia
Prior art keywords
correction
class
compounds
pharmaceutical composition
ascorbic acid
Prior art date
Application number
RU2014151103A
Other languages
Russian (ru)
Other versions
RU2597764C2 (en
Inventor
Виктор Владимирович Емельянов
Лариса Петровна Сидорова
Екатерина Андреевна Саватеева
Татьяна Сергеевна Булавинцева
Ирина Федоровна Гетте
Надежда Евгеньевна Максимова
Наталия Николаевна Мочульская
Валерий Александрович Черешнев
Олег Николаевич Чупахин
Original Assignee
Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" filed Critical Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина"
Priority to RU2014151103/15A priority Critical patent/RU2597764C2/en
Publication of RU2014151103A publication Critical patent/RU2014151103A/en
Application granted granted Critical
Publication of RU2597764C2 publication Critical patent/RU2597764C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Применение соединений класса 1,3,4-тиадиазина и их фармацевтической композиции с аскорбиновой кислотой в качестве средства коррекции экспериментального аллоксанового сахарного диабетаThe use of compounds of the class 1,3,4-thiadiazine and their pharmaceutical composition with ascorbic acid as a means of correction of experimental alloxan diabetes

Claims (1)

Применение соединений класса 1,3,4-тиадиазина и их фармацевтической композиции с аскорбиновой кислотой в качестве средства коррекции экспериментального аллоксанового сахарного диабетаThe use of compounds of the class 1,3,4-thiadiazine and their pharmaceutical composition with ascorbic acid as a means of correction of experimental alloxan diabetes
Figure 00000001
Figure 00000001
RU2014151103/15A 2014-12-16 2014-12-16 Use of compounds of 1,3,4-thiadiazine class as agent for correction of experimental alloxan diabetes RU2597764C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2014151103/15A RU2597764C2 (en) 2014-12-16 2014-12-16 Use of compounds of 1,3,4-thiadiazine class as agent for correction of experimental alloxan diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014151103/15A RU2597764C2 (en) 2014-12-16 2014-12-16 Use of compounds of 1,3,4-thiadiazine class as agent for correction of experimental alloxan diabetes

Publications (2)

Publication Number Publication Date
RU2014151103A true RU2014151103A (en) 2016-07-10
RU2597764C2 RU2597764C2 (en) 2016-09-20

Family

ID=56372537

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014151103/15A RU2597764C2 (en) 2014-12-16 2014-12-16 Use of compounds of 1,3,4-thiadiazine class as agent for correction of experimental alloxan diabetes

Country Status (1)

Country Link
RU (1) RU2597764C2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19502699A1 (en) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinones
RU2152943C1 (en) * 1995-12-28 2000-07-20 Проктер энд Гэмбл Компани Pharmaceutically acceptable salts of substituted 6h-1,3,4- -thiadiazine-2-amines and their pharmaceutical compositions
RU2157808C2 (en) * 1995-12-28 2000-10-20 Проктер энд Гэмбл Компани Substituted 6r-1,3,4-thiadiazine-2-amines and pharmaceutical composition thereof
EP1463509A1 (en) * 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
RU2364591C1 (en) * 2008-01-09 2009-08-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) Bis{3-phenyl-1-[2-(5-ethyl-1,3,4-thiadiazolyl)]carboxamido-1,3-propanedionato}cadmium, possessing hypoglycemic activity
RU2458060C2 (en) * 2009-05-22 2012-08-10 Государственное образовательное учреждение высшего профессионального образования "Уральский государственный технический университет - УПИ имени первого Президента России Б.Н. Ельцина" 5-(4'-hydroxyphenyl)-and 5-(2',5'-dihydroxyphenyl)-6 h-1,3,4-thiadiazine-2-amines, hydrohalogenides inhibiting thrombocyte aggregation in intravenous introduction
RU2447066C2 (en) * 2010-04-15 2012-04-10 Александр Леонидович Гинцбург Pathogenic bacteria-inhibiting biologically active substances and method of inhibiting pathogenic bacteria type iii secretion

Also Published As

Publication number Publication date
RU2597764C2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
CL2016002455A1 (en) Multispecific antibodies.
EA201890058A1 (en) GLUCAGON DERIVATIVE AND COMPOSITION CONTAINING A LONGERLY ACTING CONJUGATE OF THIS DERIVATIVE
BR112016015706A2 (en) compound, use of it and pharmaceutical composition
JP2014221779A5 (en)
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
DK3357523T3 (en) BLOOD PUMPS
DK3684439T3 (en) BLOOD PUMPS
BR112016018455A2 (en) compound, acid, medication, methods to prevent or treat obesity and diabetes mellitus and to inhibit an enteropeptidase, and, use of a compound.
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
DK3518892T3 (en) PHARMACEUTICAL FORMULATION CONTAINING AN INSULIN COMPOUND
EA201791454A1 (en) DRUG FORMS FOR TRANSDERMAL ADMINISTRATION
EA201691982A1 (en) 5,6-Disposable Pyridine-2-Carboxamides as Agonists of Cannabinoid Receptors
EA201790939A1 (en) TRIAZOLO [4,5-d] Pyrimidine as an agonist of cannabinoid receptor type 2
DK3554534T3 (en) PHARMACEUTICAL COMPOSITION INCLUDING INSULIN
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
EA201691983A1 (en) Pyridine-2-amides suitable as agonists of CB2
EA201491517A1 (en) N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DIHYDROXI-1-METHYL-2-OXO-3-HINOLINKARBOXAMID, ITS PREPARATION AND APPLICATION
FR3033327B1 (en) SOLID COMPOSITION OF CARBON NANOCHARGES FOR THE FORMULATIONS USED IN LEAD BATTERIES.
EA201990093A1 (en) TWO COMPONENT COMPOSITION
RU2015136958A (en) 2-aryl-2, 4-dihydroxy-2, 5-dihydro-3-heteryl-5-oxo-1n-pyrrol-1-yl-4-methylbelsolsulfanilamides having analgesic activity
RU2014151103A (en) APPLICATION OF COMPOUNDS OF THE CLASS OF 1,3,4-THIADIAZIN AND THEIR PHARMACEUTICAL COMPOSITION WITH ASCORBIC ACID AS A MEANS OF CORRECTION OF EXPERIMENTAL ALLOXAN SUGAR DIABETES
EA202091403A1 (en) 2-OXO-1-PYRROLIDINYLIMIDAZOTHIAZOLE DERIVATIVES
RU2011147626A (en) AROMATIC BLOCK-COPOLYETHERSULPHONES
RU2013134779A (en) 2- (5-Ethyl-1,3,4-thiadiazolyl) amide 2- (4-bromophenyl) -4-oxo-4-phenyl-2-butene acid, possessing analgesic activity
RU2014115406A (en) APPLICATION 8- (TRIFFORMETHYL) BENZO [F] [1,2,3,4,5] PENTATIEPIN-6-AMINE AS ANTIDEPRESSANT

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161217